SCHEMBL2946767

SCHEMBL2946767

CN(C)C1CCC(C(=O)Nc2c(C(=O)Nc3ccc(Cl)cc3)oc3cccnc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.50
▸ MEN1 O00255 5/20 0.50
▸ MAPT P10636 7/20 0.49
▸ KDM4E B2RXH2 5/20 0.49
▸ HSD17B10 Q99714 4/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ TSHR P16473 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ POLB P06746 2/20 0.49
▸ TP53 P04637 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ LMNA P02545 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MCHR1 Q99705 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946763 1.00 KMT2A (0.50) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL2950956 0.90 SMN1; SMN2 (0.48) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL2950971 0.90 SMN1; SMN2 (0.48) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL13744821 0.86 MEN1 (0.70) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL13290407 0.84 SMN1; SMN2 (0.46) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL2942797 0.84 MEN1 (0.48) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL2942795 0.84 MEN1 (0.48) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL13290955 0.83 SMN1; SMN2 (0.44) KMT2AMEN1KDM4EALDH1A1TSHR
SCHEMBL6422919 0.83 SMN1; SMN2 (0.46) KMT2AMEN1MAPTKDM4EHSD17B10
SCHEMBL4277151 0.83 SMN1; SMN2 (0.46) KMT2AMEN1MAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US claimed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US claimed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP claimed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 KMT2A 2033/4885MEN1 1453/4885MAPT 4817/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 KMT2A 1957/4885MEN1 1870/4885MAPT 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback